From emollients to biologicals: Targeting atopic dermatitis

Abstract

Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and significantly impacts patients’ lives, particularly in its severe forms. AD clinical presentation varies over the course of the disease, throughout different age groups, and across ethnicities. AD is char-acterized by a spectrum of clinical phenotypes as well as endotypes. Starting from the current de-scription of AD pathogenesis, this review explores the rationale of approved AD therapies from emollients to biologicals and introduces novel promising drugs.